Mattern Capital Management LLC Grows Stock Holdings in Novo Nordisk A/S $NVO

Mattern Capital Management LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 55.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 46,324 shares of the company’s stock after acquiring an additional 16,524 shares during the quarter. Mattern Capital Management LLC’s holdings in Novo Nordisk A/S were worth $1,702,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Quotient Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after purchasing an additional 177 shares during the period. Certuity LLC grew its position in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after buying an additional 177 shares in the last quarter. Oakworth Capital Inc. increased its stake in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares during the period. True North Advisors LLC increased its stake in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the period. Finally, Asio Capital LLC raised its holdings in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock valued at $274,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $49.28 on Tuesday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The firm has a market cap of $220.04 billion, a PE ratio of 11.57, a P/E/G ratio of 4.51 and a beta of 0.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The stock has a fifty day moving average price of $45.71 and a 200-day moving average price of $45.84.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion for the quarter. Equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NVO. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price on the stock. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Finally, HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.